blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3440097

EP3440097 - MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  19.09.2024
Database last updated on 18.10.2024
FormerGrant of patent is intended
Status updated on  13.05.2024
FormerExamination is in progress
Status updated on  08.04.2024
FormerGrant of patent is intended
Status updated on  17.12.2023
FormerExamination is in progress
Status updated on  07.08.2020
FormerRequest for examination was made
Status updated on  11.01.2019
FormerThe international publication has been made
Status updated on  13.10.2017
Formerunknown
Status updated on  28.04.2017
Most recent event   Tooltip19.09.2024(Expected) grantpublished on 23.10.2024 [2024/43]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2019/07]
Inventor(s)01 / MILLER, Michael Matthew
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
02 / ALLEN, Martin Patrick
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
03 / LI, Ling
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
04 / BOWSHER, Michael S.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
05 / GILLIS, Eric P.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
06 / MULL, Eric
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
07 / ZHAO, Qian
93 Hintz Drive
Wallingford Connecticut 06492 / US
08 / SUN, Li-Qiang
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
09 / LANGLEY, David R.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
10 / SCOLA, Paul Michael
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
 [2019/07]
Representative(s)Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6312 Steinhausen / CH
[2019/07]
Application number, filing date17718218.503.04.2017
[2019/07]
WO2017US25677
Priority number, dateUS201662318417P05.04.2016         Original published format: US 201662318417 P
US20171547522731.03.2017         Original published format: US201715475227
[2019/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017176608
Date:12.10.2017
Language:EN
[2017/41]
Type: A1 Application with search report 
No.:EP3440097
Date:13.02.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 12.10.2017 takes the place of the publication of the European patent application.
[2019/07]
Type: B1 Patent specification
No.:EP3440097
Date:23.10.2024
Language:EN
[2024/43]
Search report(s)International search report - published on:EP12.10.2017
ClassificationIPC:C07K7/54, C07K7/64, A61P35/00, A61P31/00, A61K38/12
[2019/07]
CPC:
C07K7/56 (EP,EA,KR,US); C07K7/08 (EP,EA,KR,US); A61K38/12 (EP,EA,US);
A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP,KR);
A61P35/00 (EP); A61P35/04 (EP); A61P37/04 (EP);
C07K7/54 (EP,EA,US); C07K7/64 (EP,EA,US); A61K38/00 (EP,EA,KR,US);
Y02A50/30 (EP,EA,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA21.09.2018
MD21.09.2018
TitleGerman:MAKROCYCLISCHE INHIBITOREN DER PD-1/PD-L1- UND CD80/PD-L1-PROTEIN/PROTEIN-INTERAKTIONEN[2019/07]
English:MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS[2019/07]
French:INHIBITEURS MACROCYCLIQUES DES INTERACTIONS PROTÉINE-PROTÉINE PD-/PD-L1 ET CD80(-1)/PD-L1[2019/07]
Entry into regional phase21.09.2018National basic fee paid 
21.09.2018Designation fee(s) paid 
21.09.2018Examination fee paid 
Examination procedure21.09.2018Examination requested  [2019/07]
21.09.2018Date on which the examining division has become responsible
23.05.2019Amendment by applicant (claims and/or description)
11.08.2020Despatch of a communication from the examining division (Time limit: M06)
18.02.2021Reply to a communication from the examining division
19.05.2022Despatch of a communication from the examining division (Time limit: M04)
26.09.2022Reply to a communication from the examining division
18.12.2023Communication of intention to grant the patent
05.04.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.05.2024Communication of intention to grant the patent
12.09.2024Fee for grant paid
12.09.2024Fee for publishing/printing paid
12.09.2024Receipt of the translation of the claim(s)
Fees paidRenewal fee
15.04.2019Renewal fee patent year 03
31.03.2020Renewal fee patent year 04
15.04.2021Renewal fee patent year 05
21.03.2022Renewal fee patent year 06
14.03.2023Renewal fee patent year 07
13.03.2024Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2014151634  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-15 * Preparation examples * * claims 1,16,23 *;
 [X]WO2016039749  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-15 * page 4, line 3 - page 6, line 19 * * Examples * * claims 1,13 *;
 [XP]WO2016057624  (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-15 * Examples * * claims 1,11,20 *;
 [XP]WO2016077518  (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-15 * Examples ** claims 1,31,37 *;
 [XP]WO2016100285  (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-15 * Examples * * claims 1,11,17 *;
 [XP]WO2016100608  (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-15 * Examples * * claims 1,6,17 *
by applicantUS4439196
 US4447233
 US4447224
 US4475196
 US4486194
 US4487603
 US4522811
 US4596556
 US4790824
 US4941880
 US5064413
 US5312335
 US5374548
 US5383851
 US5399163
 US5399331
 US5416016
 US5811097
 US5837243
 US5922845
 WO2007005874
 US7488802
 US8008449
 US8168757
    - OKAZAKI ET AL., CURR. OPIN. IMMUNOL., (2002), vol. 14, pages 779 - 782
    - BENNETT ET AL., J. IMMUNOL., (2003), vol. 170, pages 711 - 718
    - AGATA ET AL., INT. IMMUNOL., (1996), vol. 8, pages 765 - 772
    - THOMAS, M.L., J. EXP. MED., (1995), vol. 181, pages 1953 - 1956
    - VIVIER, E ET AL., IMMUNOL. TODAY, (1997), vol. 18, pages 286 - 291
    - FREEMAN ET AL., J. EXP. MED., (2000), vol. 192, pages 1027 - 1034
    - LATCHMAN ET AL., NAT. IMMUNOL., (2001), vol. 2, pages 261 - 268
    - CARTER ET AL., EUR. J. IMMUNOL., (2002), vol. 32, pages 634 - 643
    - DONG ET AL., NAT. MED., (2002), vol. 8, pages 787 - 789
    - DONG ET AL., J. MOL. MED., (2003), vol. 81, pages 281 - 287
    - BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., (2005), vol. 54, pages 307 - 314
    - KONISHI ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 5094 - 5100
    - IWAI ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 12293 - 12297
    - BROWN ET AL., J. IMMUNOL., (2003), vol. 170, pages 1257 - 1266
    - BUTTE MJ ET AL., IMMUNITY, (2007), vol. 27, pages 111 - 122
    - PATERSON AM ET AL., J IMMUNOL., (2011), vol. 187, pages 1097 - 1105
    - YANG J ET AL., J IMMUNOL, vol. 187, no. 3, pages 1113 - 9
    - KEIR, M.E. ET AL., ANNU. REV. IMMUNOL., (2008), vol. 26
    - DONG, H. ET AL., "B7-H1 pathway and its role in the evasion of tumor immunity", J. MOL. MED., (2003), vol. 81, no. 5, pages 281 - 287
    - DONG, H. ET AL., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", NAT. MED., (2002), vol. 8, no. 8, pages 793 - 800, XP002397368

DOI:   http://dx.doi.org/10.1038/nm730
    - BARBER, D.L. ET AL., "Restoring function in exhausted CD8 T cells during chronic viral infection", NATURE, (2006), vol. 439, no. 7077, doi:doi:10.1038/nature04444, pages 682 - 687, XP002419629

DOI:   http://dx.doi.org/10.1038/nature04444
    - YANG J. ET AL., J IMMUNOL., (2011), vol. 187, no. 3, pages 1113 - 9
    - YANG J. ET AL., J IMMUNOL., (20110801), vol. 187, no. 3, pages 1113 - 9
    - HA, S.J. ET AL., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection", J. EXP. MED., (2008), vol. 205, no. 3, doi:doi:10.1084/jem.20071949, pages 543 - 555, XP007910673

DOI:   http://dx.doi.org/10.1084/jem.20071949
    - FINNEFROCK, A.C. ET AL., "PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination", J. IMMUNOL., (2009), vol. 182, no. 2, pages 980 - 987, XP002533526
    - SONG, M.-Y. ET AL., "Enhancement of vaccine-induced primary and memory CD8+ t-cell responses by soluble PD-1", J. IMMUNOTHER., (2011), vol. 34, no. 3, pages 297 - 306
    - MURATA, AM. J. PATHOL., (1999), vol. 155, pages 453 - 460
    - BALZANO, INT. J. CANCER SUPPL., (1992), vol. 7, pages 28 - 32
    - BERGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - RANADE, V.V., J. CLIN. PHARMACOL., (1989), vol. 29, page 685
    - UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1988), vol. 153, page 1038
    - BLOEMAN, P.G. ET AL., FEBSLETT., (1995), vol. 357, page 140
    - OWAIS, M. ET AL., ANTIMICROB. AGENTS CHEMOTHER., (1995), vol. 39, page 180
    - BRISCOE ET AL., AM. J. PHYSIOL., (1995), vol. 1233, page 134
    - SCHREIER ET AL., J. BIOL. CHEM., (1994), vol. 269, page 9090
    - KEINANEN, K. ET AL., FEBS LETT., (1994), vol. 346, page 123
    - KILLION, J.J. ET AL., IMMUNOMETHODS, (1994), vol. 4, page 273
    - IWAI ET AL., PROC. NATL. ACAD. SCI., (2002), vol. 99, pages 12293 - 12297
    - IWAI ET AL., INT. IMMUNOL., (2005), vol. 17, pages 133 - 144
    - HE ET AL., J. IMMUNOL., (2004), vol. 173, pages 4919 - 4928
    - ROSENBERG, S., Development of Cancer Vaccines, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 60 - 62
    - LOGOTHETIS, C., DEVELOPMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 300 - 302
    - KHAYAT, D., DEVELOPMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 414 - 428
    - FOON, K., DEVELOPMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 730 - 738
    - "Cancer Vaccines", RESTIFO, N. ET AL., Cancer: Principles and Practice of Oncology, (1997), pages 3023 - 3043
    - DRANOFF ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 3539 - 3543
    - ROSENBERG, S.A., IMMUNITY, (1999), vol. 10, pages 281 - 287
    - KIM, N ET AL., SCIENCE, (1994), vol. 266, pages 2011 - 2013
    - SUOT, R. ET AL., SCIENCE, (1995), vol. 269, pages 1585 - 1588
    - TAMURA, Y. ET AL., SCIENCE, (1997), vol. 278, pages 117 - 120
    - NESTLE, F. ET AL., NAT. MED., (1998), vol. 4, pages 328 - 332
    - KUGLER, A. ET AL., NAT. MED., (2000), vol. 6, pages 332 - 336
    - MOKYR, M. ET AL., CANCER RES., (1998), vol. 58, pages 5301 - 5304
    - KEHRL, J. ET AL., J. EXP. MED., (1986), vol. 163, pages 1037 - 1050
    - HOWARD, M. ET AL., IMMUNOLOGY TODAY, (1992), vol. 13, pages 198 - 200
    - HAHNE, M. ET AL., SCIENCE, (1996), vol. 274, pages 1363 - 1365
    - RIDGE ET AL., NATURE, (1998), vol. 393, pages 474 - 478
    - ITO, N. ET AL., IMMUNOBIOLOGY, (2000), vol. 201, no. 5, pages 527 - 540
    - WEINBERG, A. ET AL., IMMUNOL., (2000), vol. 164, pages 2160 - 2169
    - MELERO, I. ET AL., NAT. MED., (1997), vol. 3, pages 682 - 685
    - HUTLOFF, A. ET AL., NATURE, (1999), vol. 397, pages 262 - 266
    - GREENBERG, R. ET AL., SCIENCE, (1999), vol. 285, pages 546 - 551
    - BUTLER, N.S. ET AL., NATURE IMMUNOLOGY, (2012), vol. 13, pages 188 - 195
    - HOLLIGER, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - POLJAK, STRUCTURE, (1994), vol. 2, pages 1121 - 1123
    - OVERWIJK, W. ET AL., PROC. NATL. ACAD. SCI. USA, (1999), vol. 96, pages 2982 - 2987
    - ROSENBERG, S.A. ET AL., J. IMMUNOTHER. EMPHASIS TUMOR IMMUNOL., (1996), vol. 19, no. 1, pages 81 - 84
    - SCHENK ET AL., NATURE, (1999), vol. 400, pages 173 - 177
    - "Cancer Vaccines", RESTIFO ET AL., Cancer: Principles and Practice of Oncology, (1997), vol. 61, pages 3023 - 3043
    - ROSENBERG, IMMUNITY, (1999), vol. 10, pages 281 - 287
    - KIM ET AL., SCIENCE, (1994), vol. 266, pages 2011 - 2013
    - SUOT ET AL., SCIENCE, (1995), vol. 269, pages 1585 - 1588
    - TAMURA ET AL., SCIENCE, (1997), vol. 278, pages 117 - 120
    - NESTLE ET AL., NAT. MED., (1998), vol. 4, pages 328 - 332
    - KUGLER ET AL., NAT. MED., (2000), vol. 6, pages 332 - 336
    - MOKYR ET AL., CANCER RES., (1998), vol. 58, pages 5301 - 5304
    - RIDGE, J. ET AL., NATURE, (1998), vol. 393, pages 474 - 478
    - Physicians' Desk Reference Supplement, (2004), pages 608 - 610
    - FINGL ET AL., The Pharmacological Basis of Therapeutics,, (1975), page 1
    - "Special Methods in Peptide Synthesis", BARANY, G. ET AL., The Peptides: Analysis, Synthesis, Biology, ACADEMIC PRESS, (1980), vol. 2, pages 3 - 284
    - "The Fluorenylmethoxycarbonyl Amino Protecting Group", ATHERTON, E. ET AL., The Peptides: Analysis, Synthesis, Biology, ACADEMIC PRESS, (1987), vol. 9, pages 1 - 38
    - KING, D.S. ET AL., INT. J. PEPTIDE PROTEIN RES., (1990), vol. 36, pages 255 - 266
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.